Who are hepatitis A vaccine, DTaP, PCV10's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: Infanrix™, ProQuad®, Infanrix-IPV/Hib, BoostrixTM Polio, 23vPPV+TIV, Infanrix® Penta.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hepatitis-a-vaccine-dtap-pcv10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

hepatitis A vaccine, DTaP, PCV10 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

hepatitis A vaccine, DTaP, PCV10 (hepatitis A vaccine, DTaP, PCV10) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: combination vaccine. Area: Immunology.

marketed combination vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

hepatitis A vaccine, DTaP, PCV10 (hepatitis A vaccine, DTaP, PCV10) — KEMRI-Wellcome Trust Collaborative Research Program. This is a combination vaccine that stimulates the immune system to produce antibodies against hepatitis A virus, diphtheria, tetanus, pertussis, and pneumococcal pathogens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
hepatitis A vaccine, DTaP, PCV10 TARGET	hepatitis A vaccine, DTaP, PCV10	KEMRI-Wellcome Trust Collaborative Research Program	marketed	combination vaccine
Comparator: Infanrix™	Comparator: Infanrix™	Merck Sharp & Dohme LLC	marketed	Combination vaccine (inactivated toxoid and acellular pertussis)
ProQuad®	ProQuad®	Merck Sharp & Dohme LLC	marketed	Live attenuated combination vaccine
Infanrix-IPV/Hib	Infanrix-IPV/Hib	GlaxoSmithKline	marketed	combination vaccine
BoostrixTM Polio	BoostrixTM Polio	GlaxoSmithKline	marketed	Combination vaccine
23vPPV+TIV	23vPPV+TIV	Jiangsu Province Centers for Disease Control and Prevention	marketed	Combination vaccine
Infanrix® Penta	Infanrix® Penta	GlaxoSmithKline	marketed	Combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (combination vaccine class)

GlaxoSmithKline · 2 drugs in this class
KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
Radboud University Medical Center · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). hepatitis A vaccine, DTaP, PCV10 — Competitive Intelligence Brief. https://druglandscape.com/ci/hepatitis-a-vaccine-dtap-pcv10. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab